Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Grebely J., Conway B., Cunningham E.B., Fraser C., Moriggia A., Gane E., Stedman C., Cooper C., Castro E., Schmid P. et al., 2018/12. The International journal on drug policy, 62 pp. 94-103. Peer-reviewed.
ici le détail